Chronic obstructive pulmonary disease (COPD) is a progressive chronic lung disease characterized by persistent airflow limitation, typically including chronic bronchitis and emphysema, and associated with breathlessness, cough, and exacerbations.
A Chest study finds that respiratory or red flag symptoms at baseline increase the likelihood of lung cancer diagnosis within one year after screening. A Nature study identifies glucocorticoid-related genes with causal links to non-small cell lung cancer and constructs a multi-omics prognostic model.
AstraZeneca is expanding in China with a $200m upfront COPD drug license from Sino Biopharmaceutical, a $1.5bn licensing deal for Dizal's Zegfrovy, and a $15bn manufacturing and R&D investment. The deals add revenue-generating assets to its respiratory and oncology portfolios.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
The FDA extended the review deadline for AstraZeneca's camizestrant and issued a complete response letter for its COPD drug PT010. The agency also adopted a single-pivotal-trial approval policy, while AstraZeneca sold Losec rights to Cheplapharm.
Apogee Therapeutics will present Phase 2 APEX Part B data for zumilokibart on May 27, 2026. Affinity Asset Advisors increased its stake to 1.23 million shares valued at $93.21 million. The stock rose 86.9% over the past year.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
New real-world effectiveness data presented at RSVVW'26 demonstrate that GSK's Arexvy RSV vaccine was associated with a 75.6% reduction in RSV-related hospitalizations among adults aged 60 and older, with exploratory findings suggesting potential benefits for cardiovascular and respiratory complications.
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07762573 |
Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study |
RECRUITING | |
| NCT07656142 |
A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease |
NOT_YET_RECRUITING | NA |
| NCT07633314 |
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07620912 |
Sedation vs No Sedation in Mechanically Ventilated COPD Patients |
COMPLETED | PHASE2 |
| NCT07595588 |
Virtual Reality Cave vs. Simulated Home for Community Nursing Education: A Crossover Trial Comparing Student Competence, Confidence, and Satisfaction |
COMPLETED | NA |
| NCT07579052 |
CLEAR Model for Predicting Ventilatory Liberation in Severe COPD |
RECRUITING | |
| NCT07566195 |
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations |
RECRUITING | PHASE3 |
| NCT07549932 |
Adjunctive Role of Statin Therapy on Airway Inflammation and Clinical Consequences of Chronic Obstructive Pulmonary Disease |
COMPLETED | NA |
| NCT07512687 |
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia |
RECRUITING | NA |
| NCT07493798 |
Serum Potassium Prediction Using Machine Learning and Single-lead ECG |
WITHDRAWN |
